{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013503","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.003966+00:00","generated_at":"2026-05-15T08:30:11.506765+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe","bullets":["Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.","Two lead candidates: Sapu003 (everolimus IV) in Phase 1, Sapu006 (docetaxel) entering Phase 1.","Deciparticle is sub-20 nm nanomedicine for hydrophobic drugs, aiming to improve PK and reduce toxicities.","Sapu Nano seeking strategic partnerships to accelerate development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013503","json":"https://secwatch.observer/filing/0001493152-26-013503.json","markdown":"https://secwatch.observer/filing/0001493152-26-013503.md","text":"https://secwatch.observer/filing/0001493152-26-013503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315226013503/0001493152-26-013503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315226013503/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:30:11.506765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}